🇺🇸 FDA
Patent

US 11142578

Anti-MET antibodies, bispecific antigen binding molecules that bind MET, and methods of use thereof

granted A61KA61K31/537A61K47/68033

Quick answer

US patent 11142578 (Anti-MET antibodies, bispecific antigen binding molecules that bind MET, and methods of use thereof) held by REGENERON PHARMACEUTICALS, INC. expires Mon Oct 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Oct 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
26
CPC classes
A61K, A61K31/537, A61K47/68033, A61K47/6849, A61K47/6857